The Pharmaceutical Research and Manufacturers of America supports having generic companies play an equal role in monitoring drug safety, but it argues that FDA should approve all safety-related labeling changes before they are implemented.
The brand-name and generic industries are in agreement that FDA’s proposed rule to allow generic manufacturers to unilaterally change their labels to include new safety information could lead to conflicting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?